Conference Report

2006 Update on Hepatitis B Management

Source: CCO Independent Conference Coverage of the Management of Hepatitis B Virus 2006 National Institutes of Health Workshop*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

2006 Update on Hepatitis B Management

Faculty:

Adrian M. Di Bisceglie, MD, FACP
Norah Terrault, MD, MPH

CME CREDIT INFORMATION

Release Date: 06/14/06

Expiration Date: 06/13/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies of interferons and antiviral agents for the treatment of chronic hepatitis B, both approved and in development
Review approaches for avoiding the development of drug resistance during treatment of chronic hepatitis B and for treating patients infected with nucleos(t)ide-resistant hepatitis B virus
Discuss the diagnosis of chronic hepatitis B, and determination of who should be treated

Topics covered include:

Overview
Natural History in Asian Countries
Natural History in European Populations
HBV Replication and Immune Response
Noninvasive Markers
Molecular Testing in the Management of Hepatitis B
Standardization of Definitions and Therapeutic Endpoints
Pegylated Interferon Monotherapy
Approved Nucleos(t)ide Therapies
Telbivudine Studies
Tenofovir and Emtricitabine
Viral Resistance and Combination Therapy
Nucleos(t)ide Analogue Combination Therapy
Special Populations

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.